

Application No.: 10/550,039
Amendment Dated: August 15, 2006
Page 9 of 10

RECEIVED
CENTRAL FAX CENTER
AUG 15 2006

Remarks/Arguments

Claims 1, 4 - 7, 9, 12, 13, and 14 were pending in the instant application. Applicants have herewith amended claims 1, 6, and 7, and have canceled claim 13. Accordingly, claims 1, 4 - 7, 9, 12, and 14 are pending and under examination. No new matter has been added by these amendments.

On August 15, 2006, the Examiner discussed the instant application in a telephone conversation with applicants' undersigned representative. The Examiner indicated that he was further restricting the claims of the application. In particular, the Examiner stated that method claim 13 should be withdrawn as it is allegedly directed to an invention independent and distinct from the invention recited in claims 1, 4 - 7, 9, 12, and 14.

In order to expedite prosecution of the instant application, applicants have herein canceled claim 13.


The Examiner made further requests in the August 15, 2006 telephone conversation. The Examiner requested that Applicants insert "wherein" in claim 1 before the definitions for substituents R² and R³. With regard to claim 6, the Examiner requested that Applicants replace "R^{1a} to R^{1d}" with "R^{1a}, R^{1b}, R^{1c}, and R^{1d}." Finally, with regard to claim 7, the Examiner requested that Applicants replace the -N-HET group shown in formula (1B) with structure (1d) as recited in claim 1. Applicants have amended claims 1, 6, and 7 in accordance with the Examiner's requests.

Applicants believe the application is in condition for allowance and reserve the right to prosecute any canceled subject matter in timely filed continuation and/or divisional applications.

Application No.: 10/550,039
Amendment Dated: August 15, 2006
Page 10 of 10

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100870-1P US.

Respectfully submitted,



Name: John X. Haberman
Dated: August 15, 2006
Reg. No.: 55,236
Phone No.: 781-839-4736
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451-1215